06:57 AM EST, 12/18/2025 (MT Newswires) -- BeOne Medicines ( ONC ) said Thursday its BGB-B2033 antibody has received the US Food and Drug Administration's Fast Track Designation to treat adult patients with hepatocellular carcinoma.
The company is currently carrying out a phase 1 clinical study to evaluate the safety and anti-tumor activity of BGB-B2033, BeOne Medicines ( ONC ) said.